Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disorders

Bibliography

• MOORE PA, BELVEDERE 0, ORR A et al.: BLyS: member of the tumor necrosis factor family and B lymphocyte STIMULATOR Science (1999) 285:260–263.
   Google Scholar
• SHU HB, HU WH, JOHNSON H: TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. Leukocyte Biol. (1999) 65:680–683.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER P, MACKAY F, STEINER V et al.: BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. I Exp. Med. (1999) 189:1747–1756.
   PubMed Web of Science ®Google Scholar
• MUKHOPADHYAY A, NI J, ZHAI Y, YU GL, AGGARWAL BB: Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-KB, and c-Jun NH2-terminal kinase. Biol. Chem. (1999) 274:15978–15981.
   Web of Science ®Google Scholar
• TRIBOULEY C, WALLROTH M, CHAN V et al.: Characterization of a new member of the TNF family expressed on antigen presenting cells. Biol. Chem. (1999) 380:1443–1447.
   PubMed Web of Science ®Google Scholar
• GROSS JA, JOHNSTON J, MUDRI S et al.: TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature (2000) 404:995–999.
   PubMed Web of Science ®Google Scholar
• ••First report of successful in vivo treatmentof mmine SLE with a BLyS antagonist.
   Google Scholar
• NARDELLI B, BELVEDERE 0, ROSCHKE V et al: Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood (2001) 97:198–204.
   PubMed Web of Science ®Google Scholar
• JIANG Y, OHTSUJI M, ABE M et al.: Polymorphism and chromosomal mapping of the mouse gene for B-cell activating factor belonging to the tumor necrosis factor family (Baff) and association with the autoimmune phenotype. Immunogenetics (2001) 53:810–813.
   PubMed Web of Science ®Google Scholar
• KAWASAKI A, TSUCHIYA N, FUKAZAWA T, HASHIMOTO H, TOKUNAGA K: Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes _Liman. (2002) 3:424–429.
   Web of Science ®Google Scholar
• KAWASAKI A, TSUCHIYA N, FUKAZAWA T et al.: Association of TACI polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. (2003) 48(Suppl.):S383.
   Google Scholar
• SCAPINI P, NARDELLI B, NADALI G et al.: G-CSF-stimulated neutrophils are a prominent source of functional BLyS. Exp. Med. (2003) 197:297–302.
   PubMed Web of Science ®Google Scholar
• LITINSKIY MB, NARDELLI B, HILBERT DM et al.: DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat. Immunol (2002) 3:822–829.
   PubMed Web of Science ®Google Scholar
• PHILLIPS TA, NI J, HUNT JS: Cell-specific expression of B lymphocyte (APRIL, BLyS)- and Th2 (CD3OL/ CD153)-promoting tumor necrosis factor superfamily ligands in human placentas. Leukocyte Biol. (2003) 74:81–87.
   PubMed Web of Science ®Google Scholar
• TAO W, HANGOC G, HAWES JW, SI Y, COOPERS, BROXMEYER HE: Profiling of differentially expressed apoptosis-related genes by cDNA arrays in human cord blood CD34' cells treated with etoposide. Exp. Hematol (2003) 31:251–260.
   PubMed Web of Science ®Google Scholar
• JUNG DJ, BONG JJ, BAIK M: Extracellular proteinase inhibitor-accelerated apoptosis is associated with B cell activating factor in mammary epithelial cells. Exp. Cell Res. (2004) 292:115–122.
   PubMed Web of Science ®Google Scholar
• CLAUDIO JO, MASIH-KHAN E, TANG H et al.: A molecular compendium of genes expressed in multiple myeloma. Blood (2002) 100:2175–2186.
   PubMed Web of Science ®Google Scholar
• NOVAK AJ, BRAM RJ, KAY NE, JELINEK DF: Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood (2002) 100:2973–2979.
   PubMed Web of Science ®Google Scholar
• KERN C, CORNUEL JF, BILLARD C et al.: Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood (2004) 103:679–688.
   PubMed Web of Science ®Google Scholar
• NOVAK AJ, DARCE JR, ARENDT BK et al.: Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood (2004) 103:689–694.
   PubMed Web of Science ®Google Scholar
• HE B, CHADBURN A, JOU E, SCHATTNER EJ, KNOWLES DM, CERUTTI A: Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. 1 Immunol (2004) 172:3268–3279.
   PubMed Web of Science ®Google Scholar
• MOREAUX J, LEGOUFFE E, JOURDAN E et al.: BAFF and APRIL protect myeloma cells from apoptosis induced by IL-6 deprivation and dexamethasone. Blood (2004) 103:3148–3157.
   PubMed Web of Science ®Google Scholar
• HE B, RAAB-TRAUB N, CASALI P, CERUTTI A: EBV-encoded la tent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. I Immunol (2003) 171:5215–5224.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER K, KOTHLOW S, SCHNEIDER P et al.: Chicken BAFF - a highly conserved cytokine that mediates B cell survival. Int. Immunol (2004) 16:139–148.
   PubMed Web of Science ®Google Scholar
• KANAKARAJ P, MIGONE TS, NARDELLI B et al.: BLyS binds to B cells with high affinity and induces activation of the transcription factors NF-icB and ELF-1.Cytokine (2001) 13:25–31.
   PubMed Web of Science ®Google Scholar
• LIU Y, XU L, OPALKA N, KAPPLER M,SHU HB, ZHANG G: Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands. Cell (2002) 108:383–394.
   PubMed Web of Science ®Google Scholar
• KIM HM, YU KS, LEE ME et al: Crystal structure of the BAFF-BAFF-R complex and its implications for receptor activation. Nat. Struct. Biol. (2003) 10:342–348.
   PubMedGoogle Scholar
• LIU Y, HONG X, KAPPLER J et al: Ligand-receptor binding revealed by the TNF family member TALL-1.Nature (2003) 423:49–56.
   PubMed Web of Science ®Google Scholar
• KARPUSAS M, CACHERO TG, QIAN F et al.: Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes.Biol. (2002) 315:1145–1154.
   Google Scholar
• OREN DA, LI Y, VOLOVIK Y et al.: Structural basis of BLyS receptor recognition. Nat. Struct. Biol. (2002) 9:288–292.
   PubMedGoogle Scholar
• ZHUKOVSKY EA, LEE JO, VILLEGAS M,CHAN C, CHU S, MROSKE C: Is TALL-1 a trimer of a virus-like cluster? Nature (2004) 427:413–414.
   PubMedGoogle Scholar
• LAABI Y, GRAS MP, BROUET JC, BERGER R, LARSEN CJ, TSAPIS A: The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed. Nucleic Acids Res. (1994) 22:1147–1154.
   PubMed Web of Science ®Google Scholar
• VON BOLOW GU, BRAN RJ: NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science (1997) 278:138–141.
   PubMed Web of Science ®Google Scholar
• THOMPSON JS, BIXLER SA, QIAN F et al.: BAFF-R, a novel TNF receptor that specifically interacts with BAFF. Science (2001) 293:2108–2111.
   PubMed Web of Science ®Google Scholar
• •One of first reports indicating that BAFFR is the key receptor for the agonist effects of BLyS.
   Google Scholar
• YAN M, BRADY JR, CHAN B et al: Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curt: Biol. (2001) 11:1547–1552.
   PubMed Web of Science ®Google Scholar
• •One of first reports indicating that BAFFR is the key receptor for the agonist effects of BLyS.
   Google Scholar
• XIA XZ, TREANOR J, SENALDI G et al.: TACT is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation. J. Exp. Med. (2000) 192:137–143.
   PubMed Web of Science ®Google Scholar
• UNDERHILL GH, GEORGE D, BREMER EG, KANSAS GS: Gene expression profiling reveals a highly specialized genetic program of plasma cells. Blood (2003) 101:4013–4021.
   PubMed Web of Science ®Google Scholar
• TARTE K, ZHAN F, DE VOS J, KLEIN B, SHAUGHNESSY J Jr: Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood (2003) 102:592–600.
   PubMed Web of Science ®Google Scholar
• AVERY DT, KALLED SL, ELLYARD JI et al.: BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J. Clin. Invest. (2003) 112:286–297.
   PubMed Web of Science ®Google Scholar
• O'CONNOR BE RAMAN VS, ERICKSON LD et al.: BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. (2004) 199:91–97.
   Google Scholar
• SHU HB, JOHNSON H: B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1.Proc. Natl. Acad. Sci. USA (2000) 97:9156–9161.
   PubMed Web of Science ®Google Scholar
• HATZOGLOU A, ROUSSEL J, BOURGEADE MF et al.: TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-icB, Elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. Innnunal (2000) 165:1322–1330.
   Google Scholar
• XU LG, SHU HB: TNFR-associated factor-3 is associated with BAFF-R and negatively regulates BAFF-R-mediated NF-icB activation and IL-10 production. Immunol. (2002) 169:6883–6889.
   Web of Science ®Google Scholar
• HIKIDA M, JOHMURA S, HASHIMOTO A, TAKEZAKI M, KUROSAKI T: Coupling between B cell receptor and phospholipase C-72 is essential for mature B cell development. Exp. Med. (2003) 198:581–589.
   PubMed Web of Science ®Google Scholar
• CLAUDIO E, BROWN K, PARKS, WANG H, SIEBENLIST U: BAFF-induced NEMO-independent processing of NK-icB2 in maturing B cells. Nat. Immune]. (2002) 3:958–965.
   Google Scholar
• KAYAGAKI N, YAN M, SESHASAYEE D et al.: BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-icB2.binnunio, (2002) 10:515–524.
   Google Scholar
• ••Describes successful in vivo treatment of mtuine SLE with an antagonist specific only for BLyS and not for APRIL.
   Google Scholar
• HATADA EN, DO RKG, ORLOFSKY A et al.: NF-icB1 p50 is required for BLyS attentuation of apoptosis but dispensible for processing of NF-icB2 p100 to p52 in quiescent mature B cells. J. binnunal (2003) 171:761–768.
   Google Scholar
• THOMPSON JS, SCHNEIDER P, KALLED SL et al.: BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J. Exp. Med. (2000) 192:129–135.
   PubMed Web of Science ®Google Scholar
• DO RK, HATADA E, LEE H, TOURIGNY MR, HILBERT D, CHEN-KIANG S: Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J. Exp. Med. (2000) 192:953–964.
   PubMed Web of Science ®Google Scholar
• BATTEN M, GROOM J, CACHERO TG et al.: BAFF mediates survival of peripheral immature B lymphocytes. I Exp. Med. (2000) 192:1453–1465.
   PubMed Web of Science ®Google Scholar
• HARLESS SM, LENTZ VM, SAH AP et al.: Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbers. Can: Biol. (2001) 11:1986–1989.
   Google Scholar
• HSU BL, HARLESS SM, LINDSLEY RC, HILBERT DM, CANCRO MP: Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J. binnunal (2002) 168:5993–5996.
   Google Scholar
• AMANNA IJ, DINGWALL JP, HAYES CE: Enforced bc/-xL gene expression restored splenic B lymphocyte development in BAFF-R mutant mice. Irnmunol. (2003) 170:4593–4600.
   PubMed Web of Science ®Google Scholar
• TARDIVEL A, TINEL A, LENS S et al.:The anti-apoptotic factor Bc1-2 can functionally substitute for the B cell survival but not for the marginal zone B cell differentiation activity of BAFF. Ear. J. Irinnunol. (2004) 34:509–518.
   PubMed Web of Science ®Google Scholar
• BALAZS M, MARTIN F, ZHOU T, KEARNEY JF: Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity (2002) 17:341–352.
   PubMed Web of Science ®Google Scholar
• WILLIAMS-BLANGERO S, VANDEBERG JL, SUBEDI J et al.: Genes of chromosomes 1 and 13 have significant effects on Ascatis infection. Proc. Natl. Acad. Sci. USA (2003) 99:5533–5538.
   Web of Science ®Google Scholar
• GROSS JA, DILLON SR, MUDRI S et al: TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity (2001) 15:289–302.
   PubMed Web of Science ®Google Scholar
• •One of first reports of profound in vivo B cell defiency in BLyS-deficient mice.
   Google Scholar
• SCHIEMANN B, GOMMERMAN JL, VORA K et al.: An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science (2001) 293:2111–2114.
   PubMed Web of Science ®Google Scholar
• •One of first reports of profound in vivo B cell defiency in BLyS-deficient mice.
   Google Scholar
• GORELIK L, CUTLER AH, THILL G et al.: Cutting edge: BAFF regulates CD21/ 35 and CD23 expression independent of its B cell survival function. binnunol. (2004) 172:762–766.
   Google Scholar
• XU S, LAM DP: B-cell maturation protein,which binds the tumor necrosis factor family members BAFF and APRIL, is dispensible for humoral immune responses. Mol. Cell. Biol. (2001) 21:4067–4074.
   PubMed Web of Science ®Google Scholar
• KAWASAKI A, TSUCHIYA N, FUKAZAWA T, HASHIMOTO H, TOKUNAGA K: Presence of four major haplotypes in human BCMA gene: lack of association with systemic lupus erythematosus and rheumatoid arthritis. Genes Inman. (2001) 2:276–279.
   Web of Science ®Google Scholar
• VON BOLOW GU, VAN DEURSEN JM, BRAM RJ: Regulation of the T-independent humoral response by TACI. binnunio, (2001) 14:573–582.
   Google Scholar
• YAN M, WANG H, CHAN B et al: Activation and accumulation of B cells in TACT-deficient mice. Nat. Immunol (2001) 2:638–643.
   PubMed Web of Science ®Google Scholar
• SESHASAYEE D, VALDEZ P, YAN M, DIXIT VM, TUMAS D, GREWAL IS: Loss of TACT causes fatal lymphoproliferation and autoimmunity, establishing TACT as an inhibitory BLyS receptor. Immunity (2003) 18:279–288.
   PubMed Web of Science ®Google Scholar
• •Demonstrates that BLyS engagement of TACT can downregulate B cell function.
   Google Scholar
• HAHN BH, TSAO BP: Antibodies to DNA. In: Dubois' Lupus Elythematosus. Wallace DJ, Hahn BH (Eds), Williams & Wilkins, Baltimore (1997):407–422.
   Google Scholar
• MACKAY F, WOODCOCK SA, LAWTON P et al.: Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. Exp. Med. (1999) 190:1697–1710.
   PubMed Web of Science ®Google Scholar
• ••One of first reports detailing thatconstitutive overexpression of BLyS in vivo can lead to SLE-like manifestations.
   Google Scholar
• KHARE SD, SAROSI I, XIA XZ et al: Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc. Natl Acad. Sci. USA (2000) 97:3370–3375.
   PubMed Web of Science ®Google Scholar
• ••One of first reports detailing thatconstitutive overexpression of BLyS in vivo can lead to SLE-like manifestations.
   Google Scholar
• ZHANG J, ROSCHKE V, BAKER KP et al.: Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. Immunol (2001) 166:6–10.
   Web of Science ®Google Scholar
• ••Describes BLyS overexpression inhuman SLE.
   Google Scholar
• CHEEMA GS, ROSCHKE V, HILBERT DM, STOHL W: Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. (2001) 44:1313–1319
   PubMed Web of Science ®Google Scholar
• ••Describes BLyS overexpression inhuman SLE.
   Google Scholar
• STOHL W, METYAS S, TAN SM et al: B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. (2003) 48:3475–3486.
   PubMed Web of Science ®Google Scholar
• ••Describes BLyS overexpression inhuman SLE.
   Google Scholar
• PETRI M, STOHL W, CHATHAM W et al.: BLyS plasma concentrations correlate with disease activity and levels of anti-dsDNA autoantibodies and immunoglobulins (Ig) in a SLE patient observational study. Arthritis Rheum. (2003) 48:S655.
   Google Scholar
• BAKER KP, EDWARDS BM, MAIN SH et al.: Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. (2003) 48:3253–3265.
   PubMed Web of Science ®Google Scholar
• FURIE R, STOHL W, GINZLER E et al.: Safety, pharmacokinetic and pharmacodynamic results of a Phase I single and double dose-escalation study of Lymphostat-B (human monoclonal antibody to BLyS) in SLE patients. Arthritis Rheum. (2003) 48:S377.
   Web of Science ®Google Scholar
• PELLETIER M, THOMPSON JS, QIAN F et al: Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF. Biol. Chem. (2003) 278:33127–33133.
   Web of Science ®Google Scholar
• STEED PM, TANSEY MG, ZALEVSKY J et al.: Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science (2003) 301:1895–1898.
   PubMed Web of Science ®Google Scholar
• GAVIN AL, ATT-AZZOUZENE D, WARE CE NEMAZEE D: ABAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAH I Biol. Chem. (2003) 278:38220–38228.
   Web of Science ®Google Scholar
• HAHNE M, KATAOKA T, SCHROTER M et al.: APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. Exp. Med. (1998) 188:1185–1190.
   PubMed Web of Science ®Google Scholar
• KELLY K, MANOS E, JENSEN G, NADAULD L, JONES DA: APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death. Cancer Res. (2000) 60:1021–1027.
   PubMed Web of Science ®Google Scholar
• MARSTERS SA, YAN M, PITTI RM, HAAS PE, DIXIT VM, ASHKENAZI A: Interaction of the TNF homologues BLyS and APRIL with the receptor homologues BCMA and TACT. Can: Bid (2000) 10:785–788.
   Google Scholar
• YU G, BOONE T, DELANEY J et al: APRIL and TALL-1 and receptors BCMA and TACT: system for regulating humoral immunity. Nat. Immunol (2000) 1:252–256.
   PubMed Web of Science ®Google Scholar
• WU Y, BRESSETTE D, CARRELL JA et al.: Tumor necrosis factor (TNF) receptor superfamily member TACT is a high affinity receptor for TNF family members APRIL and BLyS. I Biol. Chem. (2000) 275:35478–35485.
   Web of Science ®Google Scholar
• RENNERT P, SCHNEIDER P, CACHERO TG et al.: A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. Exp. Med. (2000) 192:1677–1683.
   PubMed Web of Science ®Google Scholar
• PATEL DR, WALLWEBER HJ, YIN JP et al.: Engineering an APRIL-specific B-cell maturation antigen (BCMA). I Biol. Chem. (2004) 279:16727–16735.
   Web of Science ®Google Scholar
• CRAXTON A, MAGALETTI D, RYAN EJ, CLARK EA: Macrophage- and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood (2003) 101:4464–4471.
   PubMed Web of Science ®Google Scholar
• LOPEZ-FRAGA M, FERNANDEZ R, ALBAR JP, HAHNE M: Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep. (2001) 2:945–951.
   PubMed Web of Science ®Google Scholar
• STOHL W, METYAS S, TAN S-M et al: Inverse association between circulating APRIL levels and serologic and clinical disease activity in patients with systemic lupus erythematosus. Ann. Rheum. Dis. (2004). In press.
   Google Scholar
• KOYAMA T, TSUKAMOTO H, MASUMOTO K et al: A novel polymorphism of the human APRIL gene is associated with systemic lupus erythematosus. Rheumatology (2003) 42:980–985.
   PubMed Web of Science ®Google Scholar
• VARFOLOMEEV E, KISCHKEL F, MARTIN F et al.: APRIL-deficient mice have normal immune system development. MM. Cell. Biol. (2004) 24:997–1006.
   Web of Science ®Google Scholar
• STEIN JV, LOPEZ-FRAGA M, ELUSTONDO FA et al: APRIL modulates B and T cell immunity. I Clin. Invest. (2002) 109:1587–1598.
   PubMed Web of Science ®Google Scholar
• ROSCHKE V, SOSNOVTSEVA S, WARD CD et al.: BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. Immunol (2002) 169:4314–4321.
   Web of Science ®Google Scholar
• TAKEMURA S, KLIMIUK PA, BRAUN A, GORONZY JJ, WEYAND CM: T cell activation in rheumatoid synovium is B cell dependent. Immunol (2001) 167:4710–4718.
   Web of Science ®Google Scholar
• WANG H, MARSTERS SA, BAKER T et al.: TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat. Immunol (2001) 2:632–637.
   PubMed Web of Science ®Google Scholar
• RIDLEY MG, KINGSLEY G, PITZALIS C, PANAYI GS: Monocyte activation in rheumatoid arthritis: evidence for in situ activation and differentiation in joints. Br. Rheumatol. (1990) 29:84–88.
   PubMedGoogle Scholar
• TAN SM, XU D, ROSCHKE V et al.: Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritic Rheum. (2003) 48:982–992.
   PubMed Web of Science ®Google Scholar
• •Describes BLyS overexpression in human patients with various arthritides.
   Google Scholar
• GROOM J, KALLED SL, CUTLER AH et al.: Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. Clin. Invest. (2002) 109:59–68.
   Google Scholar
• •First report of overexpression of BLyS in human Sjiigren's syndrome.
   Google Scholar
• ROBINSON CP, BRAYER J, YAMACHIKA S et al.: Transfer of human serum IgG to nonobese diabetic Igilmai mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjögren's syndrome. Proc. Natl. Acad. Sci. USA (1998) 95:7538–7543.
   PubMed Web of Science ®Google Scholar
• SZODORAY P, JELLESTAD S, TEAGUE MO, JONSSON R: Attenuated apoptosis of B cell activating factor-expressing cells in primary Sjögren's syndrome. Lab. Invest. (2003) 83:357–365.
   PubMed Web of Science ®Google Scholar
• LAVIE F, MICELI-RICHARD C, QUILLARD J, ROUX S, LECLERC P, MARIETTE X: Expression of BAFF in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome. Arthritis Rheum. (2003) 48(Suppl.):565.
   Google Scholar
• MARIETTE X, ROUX S, ZHANG J et al.: The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann. Rheum. Dis. (2003) 62:168–171.
   PubMed Web of Science ®Google Scholar
• BRIONES J, TIMMERMAN JM, HILBERT DM, LEVY R: BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. Exp. Hematol. (2002) 30:135–141.
   PubMed Web of Science ®Google Scholar
• EMERY P, SZCZEPANSKI L, SZECHINSKI J et al.: Sustained efficacy at 48 weeks after single treatment course of ritwdmab in patients with rheumatoid arthritis. Arthritis Rheum. (2003) 48(Suppl.):439.
   Google Scholar